Streetbeat News

Earnings

T

AT&T (NYSE:T) reported Q4 sales of $32.02 billion, surpassing the analyst consensus estimate of $31.48 billion by 1.74% and marking a 2.17% increase from $31.34 billion in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:29 am

ELV

Elevance Health projects a decrease in medical enrollment from 47M in 2023 to a range of 45.8M-46.6M by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:14 am

ELV

Elevance Health projects its 2024 operating revenue to grow from flat to low-single digits compared to 2023 sales of $170.2 billion, which is below the consensus estimate of $174.32 billion. The company also forecasts its adjusted EPS to be greater than $37.10, slightly above the consensus estimate of $37.05.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:13 am

ELV

Elevance Health (NYSE:ELV) reported Q4 adjusted EPS of $5.62, slightly missing the consensus estimate of $5.64. However, the company's sales of $42.45B exceeded the estimate of $42.09B. Compared to last year, EPS increased by 7.46% and sales by 7.03%.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:09 am

TEL

TE Connectivity Ltd reported Q1 orders of $3.8B, a 4% increase YoY. Net sales were $3.83B, flat YoY and down 1% organically. GAAP EPS was $5.76, boosted by a tax benefit, while adjusted EPS rose 20% to $1.84. Operating margins reached 18.2%, with adjusted margins at 19.1%. Record cash flow from operations was $719M and free cash flow was $570M. The company deployed $1B in capital, including $600M to shareholders and $350M for acquiring Schaffner.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:06 am

TEL

TE Connectivity Ltd (TEL) has provided guidance for Q2 of fiscal 2024, expecting net sales of about $3.95 billion, which is slightly below the estimated $3.995 billion. The company anticipates GAAP EPS from continuing operations to be around $1.75, a 31% increase year over year, and adjusted EPS to be approximately $1.82, a 10% increase year over year, which is above the estimated $1.78.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:04 am

ELV

Elevance Health reported a Q4 benefit expense ratio of 89.2%, improving by 50 basis points from Q4 2022, and an annual benefit expense ratio of 87%, which is an improvement of 60 basis points from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:03 am

TEL

TE Connectivity (NYSE:TEL) reported Q1 adjusted EPS of $1.84, surpassing the $1.71 estimate, a 20.26% increase from last year. However, sales of $3.83B fell short of the $3.86B estimate, marking a slight 0.26% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:02 am

ELV

Elevance Health (NYSE:ELV) reported Q4 adjusted EPS of $5.65, surpassing the $5.64 estimate, marking a 15.78% increase from last year's $4.88. Sales reached $42.45B, exceeding the $42.09B estimate, up 7.03% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 11:01 am

AMD

NVDA

Shares of Advanced Micro Devices, Inc. (AMD) experienced a strong premarket rally on Wednesday, approaching the all-time high set on the previous Friday. The surge is attributed to a positive analyst action by New Street Research analyst Pierre Ferragu, who upgraded AMD from Neutral to Buy with a $215 price target. Ferragu also commented on the potential growth in AI chip spending, which could benefit Nvidia, Inc. (NVDA) and other silicon suppliers. AMD is expected to report Q4 results soon, with analysts predicting non-GAAP EPS of 77 cents and revenue of $6.12 billion. AMD's stock rose 2.11% to $171.98 in premarket trading.

Portfolio Pulse from Shanthi Rexaline

January 24, 2024 | 10:54 am